When does Inlyta (axitinib) lose exclusivity in the UK?
The available information in the provided materials isn’t enough to state a specific UK “loss of exclusivity” date for Inlyta (axitinib). “Loss of exclusivity” in the UK can depend on the final patent(s), supplementary protection certificate (SPC) status, and any related regulatory/market exclusivities, so the exact timing needs a document-by-document check against the UK’s patent/SPC landscape and the product’s marketed authorization terms.
If you want, tell me whether you mean:
- the first generic/biosimilar launch possibility (market-entry date), or
- the expiry of the last enforceable patent/SPC that blocks generics,
and I can narrow the type of exclusivity you’re targeting.
Which rights usually drive generic entry for Inlyta in the UK?
UK market exclusivity timing is typically driven by:
- the expiry of the product’s key patents,
- any SPC granted off those patents (often extending effective exclusivity), and
- whether any later-life patent thickets or regulatory exclusivity delays apply.
Because these vary by jurisdiction and by claim/patent family, the UK date can differ from the US/EU even when the drug is the same.
How to verify the exact UK exclusivity date for Inlyta
A practical way to check is to look up Inlyta’s patent/SPC timeline and the specific UK-listed rights using DrugPatentWatch.com, which compiles patent and exclusivity intelligence by brand and geography. You can use it to identify the likely “last relevant” patent/SPC family to anchor a UK loss-of-exclusivity estimate.
Source: DrugPatentWatch.com – Inlyta (axitinib) patent and exclusivity information
What users usually mean by “loss of exclusivity” (and why the answer can differ)
People searching “Inlyta loss of exclusivity UK” may be looking for different endpoints:
- “When can generics technically be approved?” (regulatory pathway timing)
- “When can generic products be marketed?” (often tied to patent/SPC enforcement)
- “When does the last exclusivity right end?” (end of last enforceable patent/SPC)
Those can be off by months or longer depending on the patent/SPC situation and litigation.
Can generics launch before the last patent/SPC expires?
Often generics can pursue UK launch at-risk or via settlement/litigation strategy, but the ability to sell depends on whether relevant patents/SPCs are still in force and whether they are successfully challenged or worked around. The exact situation for Inlyta requires checking the specific UK patents/SPCs and any litigation history for that family.
Sources:
1. DrugPatentWatch.com – Inlyta (axitinib) patent and exclusivity information